Home Ingredients Ipriflavone
Bone Health

Ipriflavone

Evidence Level
Limited
2 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

Ipriflavone is a synthetic isoflavone derivative (7-isopropoxyisoflavone) developed in the 1980s for osteoporosis. Distinguished from natural isoflavones by no significant estrogenic activity — bone effects without estrogenic concerns. Used extensively in Japan, Italy, and Hungary as prescription osteoporosis medication. Mixed clinical evidence; large 4-year IPRI study FAILED to show fracture reduction and revealed lymphocyte concerns — limiting current use.

Studied Dose 600 mg/day in three divided doses (200 mg TID with meals)
Active Compound Ipriflavone (7-isopropoxyisoflavone)

Benefits

Bone Mineral Density Support (Mixed Evidence)

Earlier Italian, Japanese, and Hungarian trials showed ipriflavone 600 mg/day modestly improved BMD in postmenopausal osteoporosis. HOWEVER, the larger, longer 4-year IPRI study (n=474) FAILED to confirm fracture reduction or BMD benefit vs placebo — significantly weakening the evidence base.

Supported by Trial 1, Trial 2

Non-Estrogenic Mechanism

Distinguishes ipriflavone from natural isoflavones (genistein, daidzein) which have estrogenic activity. Theoretical advantage for women avoiding estrogenic effects (e.g., breast cancer survivors). Mechanism: direct stimulation of osteoblasts and inhibition of osteoclasts without estrogen receptor activation.

Supported by Trial 1

Calcitonin Enhancement

Ipriflavone enhances calcitonin secretion and effect — calcitonin reduces bone resorption. One mechanism for bone effects.

Supported by Trial 1, Trial 2

Calcium Combination Effects

Some evidence that ipriflavone is more effective when combined with calcium supplementation — typical clinical use is ipriflavone 600 mg + calcium 1,000 mg + vitamin D.

Supported by Trial 1, Trial 2

Adjunct in Postmenopausal Bone Health

Used as adjunct alongside calcium/vitamin D in some European integrative protocols. Modern use limited by IPRI trial findings and lymphocyte concerns.

Supported by Trial 1

Mechanism of action

1

Direct Osteoblast Stimulation

Stimulates osteoblast proliferation and bone formation marker expression — independent of estrogen receptor mechanism.

2

Osteoclast Inhibition

Reduces osteoclast number and activity — inhibits bone resorption.

3

Calcitonin Modulation

Enhances endogenous calcitonin secretion; potentiates calcitonin effects on bone.

4

Non-Estrogenic Activity

Despite being an isoflavone derivative, ipriflavone (and its main metabolite daidzein — wait, daidzein IS estrogenic) — actually one concerning aspect is that ipriflavone is metabolized partly to daidzein, which IS estrogenic. So the 'non-estrogenic' positioning is partially compromised by metabolite considerations.

Clinical trials

1
Ipriflavone for Osteoporosis — IPRI Study (Alexandersen 2001)
PubMed

Large 4-year RCT of ipriflavone 600 mg/day vs placebo in 474 postmenopausal women with osteoporosis.

474 postmenopausal women.

FAILED to show fracture reduction or BMD benefit vs placebo. ADDITIONALLY: reduction in lymphocyte counts in 13.2% of ipriflavone group vs 4.0% in placebo — concerning safety signal. SIGNIFICANTLY WEAKENED ipriflavone evidence base; led to reduced clinical use.

2
Earlier Ipriflavone Trials — Pooled Evidence
PubMed

Earlier short-term Italian, Japanese, Hungarian trials of ipriflavone for osteoporosis.

Pooled across earlier trials.

Modest BMD improvements in 1-2 year trials. NOT replicated in larger, longer IPRI study. Highlights importance of longer follow-up and larger sample sizes for chronic disease interventions.

Side effects and drug interactions

Common Potential side effects

GI distress (most common — nausea, abdominal pain, dyspepsia).
LYMPHOCYTE REDUCTION — IPRI study showed 13.2% incidence vs 4.0% placebo; reversible upon discontinuation; warrants monitoring.
Headache.
Dizziness.
Skin reactions / rash.
Liver enzyme elevations rare.
Theoretical estrogenic effects via daidzein metabolite (modest).

Important Drug interactions

THEOPHYLLINE — ipriflavone INCREASES theophylline levels significantly (CYP1A2 inhibition); monitor theophylline levels; reduce dose if combining.
Tolbutamide — case report of increased levels.
Warfarin — possible interaction; monitor INR.
Calcium supplements — used together; calcium absorption enhanced; not a problematic interaction.
Estrogenic medications — theoretical interaction via daidzein metabolite.
Pregnancy — limited safety data; AVOID.

More Bone Health Ingredients

Bone Health
Calcium
Calcium is the most abundant mineral in the body — about 99% stored in bones and teeth, wi…
Bone Health
Vitamin D
Vitamin D is a fat-soluble vitamin and steroid hormone precursor essential for calcium abs…
Bone Health
Copper
Copper is an essential trace mineral and cofactor for over 30 enzymatic reactions, includi…
Bone Health
Ferrous Sulfate
Ferrous sulfate is the most common, cheapest, and longest-established oral iron form — rec…

Frequently asked questions about Ipriflavone

What is Ipriflavone?

Ipriflavone is a synthetic isoflavone derivative (7-isopropoxyisoflavone) developed in the 1980s for osteoporosis.

What does Ipriflavone do?

Stimulates osteoblast proliferation and bone formation marker expression — independent of estrogen receptor mechanism. In clinical research, Ipriflavone has been studied for bone mineral density support (mixed evidence), non-estrogenic mechanism, calcitonin enhancement.

Who should take Ipriflavone?

Ipriflavone may be most relevant for people interested in bone health. It has been clinically studied for bone mineral density support (mixed evidence), non-estrogenic mechanism, calcitonin enhancement. As with any supplement, consult your healthcare provider before starting, especially if you have medical conditions or take prescription medications.

How long does Ipriflavone take to work?

Most clinical trial effects appear over weeks of consistent use; individual response varies. Acute or same-day effects (where applicable) typically appear within hours, but most cumulative benefits — particularly those affecting biomarkers, mood, sleep quality, or chronic symptoms — require 4-12 weeks of regular use to fully assess. If you don't notice benefit after 12 weeks at the appropriate dose, it may not be your responder.

When is the best time to take Ipriflavone?

Ipriflavone can typically be taken with breakfast or dinner — taking with food reduces GI sensitivity for most supplements. Specific timing matters less than daily consistency for cumulative effects. Always check product labeling and follow personalized guidance from your healthcare provider.

Is Ipriflavone worth taking?

Ipriflavone has limited clinical evidence (Evidence Level 2/5 on NutraSmarts) — preliminary research suggests potential benefit, but more rigorous trials are needed. Whether it's worth taking depends on your specific goals, what you've already tried, your budget, and your overall supplement strategy. The honest framing: no supplement is essential for most people, and lifestyle factors (sleep, exercise, diet, stress management) typically produce larger effects than any single supplement. Ipriflavone is most worth trying if its evidence-supported uses align with your specific goals.

What is the recommended dosage of Ipriflavone?

The clinically studied dose for Ipriflavone is 600 mg/day in three divided doses (200 mg TID with meals). Always follow product labeling and consult a healthcare provider for personalized dosing recommendations.

What is Ipriflavone used for?

Ipriflavone is studied for bone mineral density support (mixed evidence), non-estrogenic mechanism, calcitonin enhancement. Earlier Italian, Japanese, and Hungarian trials showed ipriflavone 600 mg/day modestly improved BMD in postmenopausal osteoporosis.